Lesson plan

KCL-286

KCL-286 (C286), is a potent, orally bioavailable retinoic acid receptor beta (RARβ) agonist (EC50 = 1.9nM) with good selectivity over the RARα, and RARγ receptors. This molecule increases neurite outgrowth in vitro and stimulates sensory axon regrowth in vivo in a rodent model of crush and avulsion injury, and is being evaluated for the treatment of nerve injury. It has antiinflammatory and neuroregeneration-promoting effects in humans and is now in clinical trials for the treatment of Alzheimer's disease and spinal cord injury following positive results in animal studies.

Back to article

Article summary

KCL-286 (C286), is a potent, orally bioavailable retinoic acid receptor beta (RARβ) agonist (EC50 = 1.9nM) with good selectivity over the RARα, and RARγ receptors. This molecule increases neurite outgrowth in vitro and stimulates sensory axon regrowth in vivo in a rodent model of crush and avulsion injury, and is being evaluated for the treatment of nerve injury. It has antiinflammatory and neuroregeneration-promoting effects in humans and is now in clinical trials for the treatment of Alzheimer's disease and spinal cord injury following positive results in animal studies.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.